Company Directory / Medical Device

Public · NASDAQ:NVCRFor profitMedical DeviceZug, Switzerland, Switzerland
An Oncology Company Pioneering a Novel Therapy for Solid Tumors
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small… Read all
We are a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields. Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. We have ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. Headquartered in Switzerland, Novocure has U.S. operations in Portsmouth, New Hampshire and Chesterbrook, Pennsylvania. Additionally, Novocure has offices in Canada, Germany, Japan, Poland and Israel.
Size
1001-5000 people: larger than 97% of companies with a size listed. 1,425 people list it on LinkedIn.
Age
26 years old.
Reach
Website ranked #1,346,489 in the world for traffic, about 19k visits a month. 60,456 followers on LinkedIn.
BiotechnologyHealth CareMedical DeviceOncologyMedical DeviceOncologyCancerGlioblastomaNeuro-Oncology
Funding, as listed
$1.0B raised in total
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Everything the source datasets list about NovoCure, field by field. Contact details are held but never shown.
The company
Where
Size and reach
Funding, as listed
About this record
Growth, as the source summarises it
NovoCure reported mixed financial results for Q4 and the full year 2023. The company also reported its first quarter 2024 financial results. Additionally, NovoCure secured a new $400 million multi-tranche non-dilutive debt financing from Pharmakon.
Summaries written by the source dataset, not by us, and not checked.
Medical Device in Switzerland.
CeQur SimplicityHorw · 51-100 people · 9k followersEEndosenseMeyrin · 51-100 people · 2k followers
Aleva NeurotherapeuticsLausanne · 51-100 people · 5k followers
AliveDxEysins, Switzerland · 251-500 people · 13k followers
Medimaps GroupPlan-les-Ouates · 11-50 people · 10k followersFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,795 companies in Switzerland and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.